Rosiglitazone and pioglitazone in the treatment of diabetes mellitus

被引：2
|
作者：
Odom, Jessica [1 ]
Williamson, Bobbie [1 ]
Carter, Lucy [1 ]
机构：
[1] Greenville Hosp Syst, Greenville, SC 29605 USA
来源：
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2008年 / 65卷 / 19期
关键词：
D O I：
10.2146/ajhp070659
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1846 / 1850
页数：5
相关论文
共 50 条
  • [1] A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK
    Tilden, Dominic P.
    Mariz, Segundo
    O'Bryan-Tear, Gillies
    Bottomley, Julia
    Diamantopoulos, Alexander
    [J]. PHARMACOECONOMICS, 2007, 25 (01) : 39 - 54
  • [2] A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes Mellitus in the UK
    Home, Philip
    Bagust, Adrian
    Taylor, Matthew
    Ambery, Philip
    da Costa, Samara Mendes
    [J]. PHARMACOECONOMICS, 2007, 25 (09) : 801 - 802
  • [3] A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK
    Dominic P. Tilden
    Segundo Mariz
    Gillies O’Bryan-Tear
    Julia Bottomley
    Alexander Diamantopoulos
    [J]. PharmacoEconomics, 2007, 25 : 39 - 54
  • [4] A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK
    Philip Home
    Adrian Bagust
    Matthew Taylor
    Philip Ambery
    Samara Mendes da Costa
    [J]. PharmacoEconomics, 2007, 25 : 801 - 802
  • [5] Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus
    Irons, BK
    Greene, RS
    Mazzolini, TA
    Edwards, KL
    Sleeper, RB
    [J]. PHARMACOTHERAPY, 2006, 26 (02): : 168 - 181
  • [6] A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of Type-2 diabetes mellitus in the UK
    Tilden, D
    Mariz, S
    Diamantopoulos, A
    O'Bryan-Tear, G
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A164 - A164
  • [7] Rosiglitazone or pioglitazone in type 2 diabetes?
    de Vries, Corinne S.
    Russell-Jones, David L.
    [J]. BRITISH MEDICAL JOURNAL, 2009, 339
  • [8] A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes Mellitus in the UK - Reply
    Tilden, Dominic P.
    Mariz, Segundo
    O'Bryan-Tear, Gillies
    Bottomley, Julia
    Diamantopoulos, Alexander
    [J]. PHARMACOECONOMICS, 2007, 25 (09) : 802 - 805
  • [9] Pioglitazone in the Treatment of Diabetes Mellitus Type 2
    Zach, Herwig
    [J]. JOURNAL FUR HYPERTONIE, 2011, 15 (04): : 58 - 58
  • [10] Fluid retention and hemodilution are not associated with reduction in hematocrit and hemoglobin following pioglitazone and rosiglitazone treatment in type 2 diabetes mellitus
    Berria, R
    Belfort, R
    DeFilippis, E
    Cusi, K
    Mahankali, A
    Miyazaki, Y
    Jovanovic, L
    Cersosimo, E
    DeFronzo, R
    Gastaldelli, A
    [J]. DIABETOLOGIA, 2005, 48 : A17 - A18
12345